ABSTRACT An H,-receptor blocking antihistamine, clemastine, taken before aspirin gave complete or partial protection against flushing, rhinorrhea, cough, and headache in ten asthmatic patients with idiosyncrasy to aspirin. In five of the ten patients aspirin-precipitated bronchoconstriction was also reduced or prevented after pretreatment with clemastine. Thus histamine appears to play a part in the production of most non-respiratory symptoms occurring after aspirin ingestion in intolerant patients with asthma. Bronchial reactions might depend partly on histamine and partly on the action of other spasmogens. It is suggested that inhibition of prostaglandins of the E series by aspirin-like drugs plays a crucial part in the release of histamine from tissue stores in aspirin-sensitive asthmatic patients. Clemastine might be of use in the treatment of acute reactions to aspirin.
In some patients with bronchial asthma ingestion of aspirin leads to bronchoconstriction often accompanied by rhinorrhoea, redness of the face, and conjunctival injection (Samter and Beers, 1968) . Similar reactions can be evoked by other analgesics which inhibit the activity of cyclooxygenase (Szczeklik et al, 1975) , the enzyme that converts arachidonic acid into prostaglandin endoperoxides. It has been suggested that hypersensitivity reactions to analgesics in patients with bronchial asthma are not of immunological origin, but are due to inhibition of prostaglandin biosynthesis in their respiratory tracts (Szczeklik et al, 1975 ) and more specifically, to blockade of the generation of prostaglandins of the E series (PGEs), which accounts for the idiosyncrasy to analgesics. The evidence in favour of this hypothesis has been summarised by .
PGEs might exert their special defensive role in patients with aspirin-induced asthma through at least two mechanisms. Firstly, they are potent bronchodilators (Cuthbert, 1969) and, secondly, they inhibit histamine release from its stores (Kaliner and Austen, 1975) . Removal of PGEs by analgesics would, therefore, deprive aspirinsensitive patients of a bronchodilator, and would promote the release of histamine, to which these patients respond dramatically (Samter and Beers, 1968; Szczeklik et al, 1977) .
Methods
Ten patients (eight women, two men) aged 22 to 57 years, with a diagnosis of aspirin-induced asthma were studied. They were all in clinical remission. Three were on maintenance therapy with prednisolone, 10 mg daily. Sodium cromoglycate was stopped 15 days before the study, and bronchodilator drugs were withdrawn eight hours beforehand.
The challenge tests were done in the morning after a light breakfast. After obtaining written consent, aspirin (20-60 mg) ) . Accompanying symptoms included watery rhinorrhea in six patients, vivid scarlet flushing of head and neck in six patients, and cough in two. All these changes began to appear not sooner than 60 minutes after aspirin ingestion and increased with time.
Before the second challenge test, which followed clemastine administration, the initial PEF values did not differ significantly from those obtained at the first challenge (P>0 1). In three patients (2, 5, and 7) clemastine pretreatment resulted in total prevention of both dyspnoea and PEF fall. In two others (3 and 4) the severity of dyspnoea induced by aspirin decreased as judged by subjective symptoms, auscultation, and PEF measurements. In the other two patients (6 and 9) there was a delay of 30-50 minutes in the onset of dyspnoea, which then developed precipitously and was of similar magnitude as during the control challenge. In the remaining three patients (1, 8, and 10) the time of onset of the obstruction, its severity, and PEF changes were similar during those two challenges.
Clemastine also exerted total protection against flushing in three of six patients, and considerably attenuated the severity of the flush while delaying its onset by 60-120 minutes in the remaining three subjects. Of six patients who responded with rhinorrhea to aspirin, clemastine pretreatment resulted in lack of nasal discharge at the repeated challenge in three (cases 5, 7, and 9) and attenuation and delay of this reaction in the remaining three (2, 6, and 8). Clemastine also gave full protection against cough in two patients and against headache and tinnitus in another one.
Nine days after the second challenge, a third one using the same dose of aspirin was repeated in two patients. Clinical symptoms and PEF behaviour were very much the same as during the first challenge, preceding clemastine administration (figure). The protective effect of clemastine on aspirininduced bronchoconstriction was less evident. The protection was complete in some patients, partial in some, and absent in others. It might, therefore, be assumed that histamine is not the sole final mediator responsible for aspirin-induced bronchoconstriction in hypersensitive subjects. Other spasmogens might play a more important part in those patients who experienced little or no protection from clemastine.
Participation of histamine in aspirin-induced bronchoconstriction was suggested by recent studies. Thus Stevenson et al (1976) observed significant rises in plasma histamine after aspirin challenge in aspirin-sensitive asthmatics, but not in asthmatic patients without this sensitivity or in control subjects. Several authors have also reported on inhibition of aspirin-precipitated bronchospasm by sodium cromoglycate in hypersensitive patients (Basomba et al, 1976; Delaney, 1976; Martelli and Usandivaras, 1977; Pasargiklian et al, 1977) . Sodium cromoglycate appears to stabilise mast cell membranes and to inhibit the action of intravenous histamine that is dependent on a-adrenergic receptors (Kerr et al, 1970) . This action of sodium cromoglycate might explain its good therapeutic effects in some patients with aspirin-induced asthma (Gwin et al, 1977; Szczeklik et al, 1977) .
We believe (Szczeklik et al, 1975 (Szczeklik et al, , 1977 that the release of histamine from its stores here discussed results from blockade generation of PGEs by analgesics. This concept is supported by the results of studies showing that in-vitro PGEs inhibit release of histamine from human lung slices (Walker, 1973) and human basophil preparations (Lichtenstein and Bourne, 1971) . Furthermore, the antigen-induced release of histamine from human basophils is considerably increased after blockade of PGEs generation by aspirin (Okazaki et al, 1977) . The stabilising effect of PGEs on mast cells and basophils appears to be connected with their ability to increase cyclic AMP (Kaliner and Austen, 1975) . It should therefore be noticed that prostacyclin, a recently discovered arachidonate metabolic (Gryglewski et al, 1976) , is a more potent stimulator of cAMP than PGEs (Gorman et al, 1977) . Prostacyclin. however, appears to act primarily in the vascular bed, as a circulating hormone . Furthermore, it has little, if any, bronchodilator effect in asthmatic patients, including those with aspirin-sensitive asthma .
Our results suggest that clemastine might be helpful in the treatment of acute adverse reactions to aspirin. An inhalation should be most suitable in these cases, since inhaled clemastine causes bronchodilatation in patients with asthma (Nogrady et al, 1978) . It remains to be seen whether prolonged treatment with clemastine could benefit patients with aspirin-induced asthma. 
